Age |
Number of cases |
Percentage % |
1-10 years |
16 |
10.00 |
11-20 years |
24 |
15.00 |
21-30 years |
47 |
29.38 |
31-40 years |
35 |
21.88 |
41-50 years |
17 |
10.62 |
51-60 years |
9 |
05.62 |
61-70 years |
7 |
04.38 |
71-80 years |
5 |
03.12 |
Total |
160 |
100 |
Mean age + SD |
31.07 + 16.86 |
|
Clinical Types of primary pyodermas |
No. of patients |
Percentage (%) |
Clinical types of secondary pyodermas |
No. of patients |
Percentage |
Impetigo contagiosa |
16 |
31.40 |
Infected eczema |
55 |
50.46 |
Furuncle |
11 |
21.56 |
Infected ulcer |
40 |
36.70 |
Folliculitis |
10 |
19.60 |
Pustular lesions |
08 |
07.34 |
Cellulitis |
4 |
07.84 |
Infected scabies |
02 |
01.83 |
Paronychia |
4 |
07.84 |
Infected psoriasis |
01 |
00.92 |
Carbuncle |
3 |
05.88 |
Irritant contact
dermatitis with secondary infection |
02 |
01.83 |
Bullous impetigo |
3 |
05.88 |
Herpes zoster with
secondary infection |
01 |
00.92 |
Total |
51 |
100.00 |
Total |
109 |
100.00 |
Organisms isolated in primary pyodermas |
No. Of patients (n=51) |
Percentage % |
Organisms isolated in secondary pyodermas |
No of patients |
Percentage % |
|||
Staphylococcus |
MSSA |
20 |
39.22 |
Staphylococcus |
MSSA |
46 |
42.20 |
|
Aureus |
MRSA |
0 |
00.00 |
Aureus |
MRSA |
4 |
03.67 |
|
Coagulase negative
Staphylococcus |
8 |
15.69 |
Escherichia coli |
|
16 |
14.68 |
||
Klebsiellaspp |
4 |
07.84 |
Coagulase negative
Staphylococcus |
|
12 |
11.00 |
||
Enterococcus spp |
VSE |
4 |
07.84 |
Pseudomonas aeruginosa |
|
8 |
07.34 |
|
VRE |
0 |
00.00 |
Proteus spp |
|
7 |
06.42 |
||
Pseudomonas aeruginosa |
4 |
07.84 |
Klebsiellaspp |
4 |
|
03.67 |
||
Citrobacterspp |
2 |
03.92 |
Enterococcus |
VSE |
5 |
04.60 |
||
No growth |
9 |
17.65 |
|
VRE |
1 |
00.92 |
||
|
|
|
Acinetobacterspp |
2 |
|
01.83 |
||
|
|
|
Citrobacterspp |
1 |
|
00.92 |
||
|
|
|
No growth |
3 |
|
02.75 |
Antibiotic tested |
Staphylococcus aureus(n=70) |
CONS (n=20) |
Enterococcus (n=10) |
E.coli (n=16) |
Pseudo (n=12) |
Klebsiella (n=8) |
Proteus (n=7) |
Citrobacter (n=3) |
Acinetobacter (n=2) |
Ampicillin |
S11(15.71) |
S5(25) |
S2(20) |
NT |
NT |
NT |
NT |
NT |
NT |
Amikacin |
S67(95.71) |
S17(85) |
S8(80) |
S15(93.75) |
S11(91.66) |
S8(100) |
S6(85.71) |
S3(100) |
NT |
Gentamycin |
S51(72.85) |
S14(70) |
S7(70) |
S12(75) |
S10(83.33) |
S7(87.50) |
S5(71.43) |
S2(66.66) |
S1(50) |
Ciprofloxacin |
S35(50.00) |
S14(70) |
S6(60) |
S10(62.50) |
S10(83.33) |
S5(41.60) |
S4(57.14) |
S3(100) |
S1(50) |
Erythromycin |
S53(75.71) |
S15(75) |
S8(80) |
NT |
NT |
NT |
NT |
NT |
NT |
Cephalexin |
S27(38.57) |
S8(40) |
S5(50) |
NT |
NT |
NT |
NT |
NT |
NT |
Cefoxitin |
S66(94.28) R4(5.71) |
S20(100) |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
Cotrimoxazole |
S39(55.71) |
S12(60) |
S6(60) |
NT |
NT |
NT |
NT |
NT |
NT |
Linezolid |
S70(100) |
S20(100) |
S10(100) |
NT |
NT |
NT |
NT |
NT |
NT |
Vancomycin |
S70(100) |
S20(100) |
S9(90) |
NT |
NT |
NT |
NT |
NT |
NT |
A-clav |
S66(94.28) |
S20(100) |
NT |
NT |
NT |
NT |
NT |
NT |
NT |
Ceftazidime |
NT |
NT |
NT |
S10(62.50) |
S5(41.66) |
S3(37.50) |
S2(28.57) |
S1(33.33) |
S0(0) |
Pipercillin-tazobactam |
NT |
NT |
NT |
S15(93.75) |
S11(91.66) |
S8(100) |
S7(100) |
S3(100) |
S2(100) |
Salbactam-ceftazidime |
NT |
NT |
NT |
S13(81.25) |
S10(83.33) |
S7(87.50) |
S5(71.43) |
S3(100) |
S2(100) |
Imipenem |
NT |
NT |
NT |
S16(100) |
S12(100) |
S8(100) |
S7(100) |
S3(100) |
S2(100) |